

Special Issue

New Advances in Kaposi's Sarcoma-Associated Herpesvirus Research

Message from the Guest Editor

Discovered in 1994, Kaposi's sarcoma-associated herpesvirus (KSHV) is one of seven oncogenic viruses and one of two herpesviruses associated with human cancer. Unlike small DNA tumour viruses, KSHV is not constrained by genetic economy. With over 85 protein-coding regions (that we know of), this herpesvirus is a master manipulator. KSHV deregulates antiviral responses, hijacks stress signaling and metabolic pathways, elicits aberrant cell proliferation and induces angiogenesis while reprogramming immune responses so that the virus can persist in a chronic latent state. Such complex virus-host interplay must be understood in molecular detail if we seek to intervene and treat these chronic infections without causing harm. In addition, as has so often been the case in the past, understanding how viruses manipulate and subvert our host defenses provides a window into the complexities of immune system regulation.

Guest Editor

Dr. Jennifer Corcoran

Department of Microbiology, Immunology and Infectious Diseases,
University of Calgary, Calgary, AB, Canada

Deadline for manuscript submissions

closed (31 October 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/42206

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).